Nanoviricides Inc (NNVC) Stock Price, Quote & News

Company Profile

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 937 6137

Website: www.nanoviricides.com

Address:

1 Controls Drive, Shelton, United States

STRAYNUT Oct. 25 at 7:33 PM

$NNVC Short Interest (10/15/25) Shares Sold Short 46,270 Change from Last -21.11% Percent of Float 0.28% https://www.wsj.com/market-data/quotes/NNVC

0 · Reply

drkazmd65 Oct. 24 at 3:57 PM

$NNVC - Alrighty Diwan,... Get something moving already.

0 · Reply

NVDAMillionaire Oct. 23 at 6:27 PM

$NNVC Excellent article that nails exactly where NNVC stands right now. So if you want to update your NNVC knowledge or get acquainted with NNVC, this is a must read. https://beyondspx.com/quote/NNVC/analysis/nanoviricides-unlocking-antiviral-revolution-with-host-mimetic-nanomedicine

0 · Reply

MahiMe Oct. 22 at 12:46 PM

$NNVC $NNVC In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides https://www.stocktitan.net/news/NNVC/in-treating-measles-infection-nv-387-showed-strong-antiviral-oasi8vzsyxk7.html

0 · Reply

tomzprofit Oct. 21 at 10:33 PM

$NNVC

0 · Reply

tomzprofit Oct. 21 at 10:30 PM

$NNVC

0 · Reply

Love1010 Oct. 21 at 10:02 PM

$NNVC someone is high on crack

0 · Reply

STRAYNUT Oct. 21 at 11:53 AM

$NNVC A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/a-measles-drug-with-strong-activity-without-toxicity-can-be-available-1089144

0 · Reply

Winning_calls Oct. 20 at 2:35 AM

$NNVC pick me up @ $1.53

0 · Reply

Another_Voice Oct. 19 at 6:24 PM

@lecorb

1 · Reply

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

Oct 20, 2025, 8:45 AM EDT - 5 days ago

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

Oct 15, 2025, 8:45 AM EDT - 10 days ago

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses

Sep 30, 2025, 8:45 AM EDT - 25 days ago

NanoViricides, Inc. Has Filed its Annual Report

Sep 11, 2025, 8:30 AM EDT - 6 weeks ago

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Sep 9, 2025, 8:30 AM EDT - 6 weeks ago

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Aug 18, 2025, 8:30 AM EDT - 2 months ago

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Jul 30, 2025, 8:30 AM EDT - 3 months ago

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

Jul 23, 2025, 8:30 AM EDT - 3 months ago

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Jul 21, 2025, 6:30 AM EDT - 3 months ago

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

Jul 16, 2025, 8:30 AM EDT - 3 months ago

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

Jun 18, 2025, 6:30 AM EDT - 4 months ago

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

Jun 4, 2025, 6:55 AM EDT - 5 months ago

NanoViricides Measles Drug Development Animal Study is Imminent

May 28, 2025, 6:30 AM EDT - 5 months ago

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

May 22, 2025, 6:30 AM EDT - 5 months ago

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

May 14, 2025, 6:30 AM EDT - 5 months ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

May 5, 2025, 6:30 AM EDT - 6 months ago

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

Apr 29, 2025, 6:30 AM EDT - 6 months ago

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

Apr 14, 2025, 6:30 AM EDT - 6 months ago

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

Mar 11, 2025, 6:30 AM EDT - 8 months ago

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

Mar 4, 2025, 6:30 AM EST - 8 months ago

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

Feb 19, 2025, 6:30 AM EST - 8 months ago

NanoViricides, Inc. Has Filed its Quarterly Report

Feb 11, 2025, 6:30 AM EST - 9 months ago

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

Jan 29, 2025, 6:30 AM EST - 9 months ago

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

Jan 27, 2025, 6:30 AM EST - 9 months ago

NanoViricides Engages CRO for Phase II Clinical Trial

Jan 13, 2025, 6:30 AM EST - 10 months ago

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

Jan 8, 2025, 6:30 AM EST - 10 months ago

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

Dec 23, 2024, 6:30 AM EST - 10 months ago

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

Nov 15, 2024, 6:30 AM EST - 1 year ago

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

Nov 4, 2024, 12:00 AM EST - 1 year ago

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am

Oct 22, 2024, 6:30 AM EDT - 1 year ago

NanoViricides President Dr. Diwan to Present at the PODD Conference

Oct 15, 2024, 6:30 AM EDT - 1 year ago

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology

Oct 8, 2024, 6:30 AM EDT - 1 year ago

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

Sep 30, 2024, 6:30 AM EDT - 1 year ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

Sep 26, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs

Aug 26, 2024, 7:30 AM EDT - 1 year ago

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

Aug 19, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections

Aug 8, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?

Aug 1, 2024, 6:30 AM EDT - 1 year ago

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides

Jul 24, 2024, 6:30 AM EDT - 1 year ago

COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides

Jul 11, 2024, 6:30 AM EDT - 1 year ago

A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides

Jun 24, 2024, 6:00 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides

Jun 20, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

Jun 11, 2024, 6:30 AM EDT - 1 year ago

Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

Jun 4, 2024, 6:30 AM EDT - 1 year ago

The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect

May 20, 2024, 6:30 AM EDT - 1 year ago

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure

May 15, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Has Filed its Quarterly Report

May 14, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral with Activity Against RSV

May 10, 2024, 6:30 AM EDT - 1 year ago

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City

STRAYNUT Oct. 25 at 7:33 PM

$NNVC Short Interest (10/15/25) Shares Sold Short 46,270 Change from Last -21.11% Percent of Float 0.28% https://www.wsj.com/market-data/quotes/NNVC

0 · Reply

drkazmd65 Oct. 24 at 3:57 PM

$NNVC - Alrighty Diwan,... Get something moving already.

0 · Reply

NVDAMillionaire Oct. 23 at 6:27 PM

0 · Reply

MahiMe Oct. 22 at 12:46 PM

0 · Reply

tomzprofit Oct. 21 at 10:33 PM

$NNVC

0 · Reply

tomzprofit Oct. 21 at 10:30 PM

$NNVC

0 · Reply

Love1010 Oct. 21 at 10:02 PM

$NNVC someone is high on crack

0 · Reply

STRAYNUT Oct. 21 at 11:53 AM

0 · Reply

Winning_calls Oct. 20 at 2:35 AM

$NNVC pick me up @ $1.53

0 · Reply

Another_Voice Oct. 19 at 6:24 PM

@lecorb

1 · Reply

SPACEDAD Oct. 17 at 6:32 PM

$NNVC $RVP $ATGN all look tasty to buy here to me. On close watch. $TXMD at $1.16 is already paying off.

0 · Reply

lecorb Oct. 17 at 3:27 PM

$NNVC $XRTX $RANI $ARTV $VHC I'm going to start blocking the damn piranhas. They're worse than flies. There are many companies on the decline with leverage for a justifiable reason, but they're piranhas and don't even respect themselves. The block has already started. I prefer fewer followers than these scavengers.

0 · Reply

lecorb Oct. 17 at 2:52 PM

$NNVC Push Baby!

0 · Reply

CalculatedSwing Oct. 17 at 2:32 PM

$NNVC

0 · Reply

lecorb Oct. 16 at 4:03 PM

@taxplanr $NNVC October 15, 2025 10:10 AM InvestorNewsBreaks - NanoViricides Featured in Analyst Report Highlighting Dual-Track Clinical Strategy for NV-387 NanoViricides, Inc. announced that Proactive Investors published an analyst research report detailing the Company’s dual-track clinical development strategy for NV-387, its broad-spectrum antiviral drug candidate targeting both MPox and respiratory viral infections, including influenza, coronaviruses, and RSV. The report notes NV-387’s nano-polymer micelle technology, which binds and neutralizes virus particles before they infect cells. Following completion of a Phase 1 safety and tolerability study in 2023, NanoViricides plans to initiate a Phase 2 trial for MPox in Congo by late 2025 or early 2026, with ethics approval already secured. The report also highlights potential U.S. biodefense funding opportunities through BARDA based on successful trial outcomes. To view the full press release, visit https://ibn.fm/ib5Cg

0 · Reply

lecorb Oct. 16 at 3:46 PM

@taxplanr $NNVC $PFE $BNTX $JNS $MRK You did not understand my post, it is not because of BNTX , it is because of the interest of large companies in NNVC for their Viral work for Covid.

1 · Reply

lecorb Oct. 16 at 1:34 PM

$NNVC $PFE $BNTX $JNS $MRK This Clinical-stage Biotech Company is Taking Its Revolutionary Platform to Help Eradicate Many Respiratory Viruses: a SINGLE drug treats RSV, FLU/Birdflu, long COVID plus monkey-pox & measles, and may even help lower the risk of metastatic cancer returning in patients following viral infections. https://profiles.smallcapsdaily.com/nnvc/?utm_source=interactiveoffers&utm_medium=email&utm_campaign=22032&utm_term=marketbeat.com&utm_content=59180&c=0&h=1&sub=&ax_09Am1=HC0HK&iocid=84ccb517e177a81f0eee5697b9e18c7e1caa7d70

0 · Reply

DARKP00L Oct. 15 at 12:47 PM

$NNVC 08:47 on Oct. 15 2025 NanoViricides Reports That An Analyst Research Report Was Published On The Company That Explains Its Dual-Track Clinical Trials For NV-387 Targeting MPox And Respiratory Viruses #tradeideas

0 · Reply

CalculatedSwing Oct. 13 at 5:12 PM

$NNVC 🚀 unleashing NV-387 Phase II beast mode: Ethics approval locked for MPox trials in DRC, eyeing ~$1B US stockpile jackpot! Phase I crushed with ZERO dropouts, measles animal study revving up—nanotech antiviral moonshot at $1.37? Analysts buzzing! Degen biotech squad: $OCGN $BTAI $TNXP $SINT – virus slayers & nano disruptors primed to explode! Load up! 🦠💉📈 #BiotechBulls #PennyVirals

0 · Reply

STRAYNUT Oct. 9 at 8:02 PM

$NNVC Short Interest (09/30/25) Shares Sold Short 58,654 Change from Last -74.71% Percent of Float 0.35% https://www.wsj.com/market-data/quotes/NNVC

0 · Reply

Camper_trader Oct. 7 at 12:09 PM

$NNVC waste time buy plug much better

0 · Reply

BiotechBrawler Oct. 5 at 2:02 PM

$NNVC Biotech speculation. Pre-revenue stage. Chart shows high risk/reward. No pattern recognition.

1 · Reply

Market Cap	26.67M
Revenue (ttm)	0.00
Net Income (ttm)	-9.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	255,300
Avg Vol	159,172
Day's Range	N/A - N/A
Shares Out	17.43M
Stochastic %K	70%
Beta	1.16
Analysts	Strong Sell
Price Target	$6.50